Clinical Variables and Dyspnea and Fear of Movement in Chronic Obstructive Pulmonary Patients

COPD Clinical Trial

Official title:

Examination of the Relationship Between Clinical Variables and Dyspnea and Fear of Movement in Chronic Obstructive Pulmonary Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06442059
• Other study ID #: Kirikkaleu-Caglanyetim
• Status: Recruiting
• Start date: October 1, 2023
• Est. completion date: October 1, 2024

Study information

• Verified date: May 2024
• Source: Kirikkale University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Patients diagnosed with COPD who applied to the Pulmonary Diseases Department of Kırıkkale Yüksek İhtisas Hospital will be included in the study. The aim of our study: It is aimed to investigate the effect of fear of movement due to dyspnea on respiratory function, muscle strength, physical performance and balance in Chronic Obstructive Pulmonary Disease Patients.

Description:

At Kırıkkale Yüksek İhtisas Hospital, individuals with COPD who meet the inclusion and exclusion criteria and volunteer to participate in the study will be included. The number of patients to be included in our study will be determined by power analysis.

Sociodemographic information (Age, Gender, Body Mass Index, Smoking history) of the individuals included in the research will be recorded.

Regarding COPD symptoms:

Whether the cough is productive or non-productive, its frequency and period Presence of sputum, type, amount, color, presence of hemoptysis, Presence of chest pain, Presence of peripheral edema, You will be asked about the presence of resting and/or exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea (PND).

1. Respiratory Muscle Strength: It will be measured using an electronic, mobile, intraoral pressure measuring device.

2. Peripheral Muscle Strength Evaluation: Quadriceps muscle strength will be evaluated using a dynomometer.

3. Physical Performance: A 6-minute walk test will be used to determine the physical fitness levels of individuals.

4. Balance Level: Mini-BEST Test will be used to determine the balance level

5. Kinesiophobia Level Due to Dyspnea:

It will be evaluated with the Breathlessness Beliefs Questionnaire (BBQ). When the literature was examined, no study was found that examined all of these factors together in patients with COPD. Existing studies have shown that the effects of variables are different and it is stated that more studies are needed.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 29
• Est. completion date: October 1, 2024
• Est. primary completion date: October 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 45 Years to 85 Years

Eligibility

Inclusion Criteria:

• Being diagnosed with COPD Be clinically stable for the last four weeks Not using antibiotics for the last four weeks being over 45 years old, Volunteering to participate in the study

Exclusion Criteria:

• Not being able to cooperate with the evaluations to be made, Having any physical disability that may affect walking and balance Having severe neuromuscular, musculoskeletal and rheumatological problems accompanying COPD

Related Conditions & MeSH terms

• COPD
• Dyspnea
• Kinesiophobia

Intervention

Other:
• Kinesiophobia Level Due to Dyspnea
Kinesiophobia Level Due to Dyspnea

Locations

Country	Name	City	State
Turkey	Saniye Aydogan Arslan	Kirikkale

Sponsors (1)

Lead Sponsor	Collaborator
Kirikkale University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Kinesiophobia Level Due to Dyspnea	It will be evaluated with the Breathlessness Beliefs Questionnaire (BBQ).BBQ; It is a scale consisting of 11 questions that evaluates the person's kinesiophobia and anxiety due to breathlessness. Patients give scores to each question ranging from 1 (strongly disagree) to 5 (strongly agree). High scores indicate high levels of kinesiophobia and anxiety due to breathlessness.	12 moon